Intercept has unveiled a $500 million philanthropic initiative aimed at reducing infections caused by respiratory viruses such as the common cold, influenza and coronaviruses. The nonprofit plans to support the development of tools that could lower transmission and, over time, make many of these illnesses far less common.
The group says its strategy centers on two categories of products: broad-spectrum preventatives that protect against multiple viruses at once, and air-cleaning technologies that reduce the number of pathogens circulating in indoor spaces. Intercept argues that neither approach alone is likely to be enough, but that the combination could meaningfully cut infection rates in schools, offices and public transit.
The initiative was introduced in a post by Nan Ransohoff, Charlie Petty and Devin Sok, who said the effort builds on discussions with scientists, biotech investors, pharma researchers and regulatory experts. The team said a symposium it helped host last year with about 40 experts suggested the biggest barrier to progress was not just technical difficulty, but a persistent lack of funding.
According to Intercept, respiratory viruses remain a major public health and economic burden even in non-pandemic years. The organization cites estimates that healthy people spend roughly two to three weeks each year sick with such infections, and says the viruses are responsible for billions of infections globally. It also points to evidence linking common respiratory infections to more severe outcomes, including lower respiratory disease and longer-term health risks.
Intercept’s founders argue that the field has lagged partly because respiratory viruses are highly diverse and mutate quickly, making broad protection difficult. They say recent advances in protein design, immunology and biological data give researchers better tools than before to tackle the problem. But they also contend that the work has historically fallen between traditional sources of support, with projects too early or too broad for commercial development and too product-focused for many philanthropies.
The nonprofit will focus first on broad-spectrum preventatives, which could include shots, pills or nasal sprays designed to offer protection against multiple respiratory viruses. Intercept says its goal is to encourage products that are safe, tolerable and easy to use, while still preventing most symptomatic infections. The organization is interested in several scientific approaches, including immune-based strategies, direct antiviral drugs, host-directed therapies and physical barrier formulations.
The second pillar is air-cleaning technology. Intercept says its most promising options include air filtration and far-UVC light, particularly in crowded indoor settings where transmission is more likely. The group says these technologies could work alongside preventatives by reducing the amount of virus people are exposed to in the first place.
The nonprofit frames the effort as a long-term public health project with implications beyond seasonal illness. It argues that broad protection against respiratory pathogens could also reduce the risk of future pandemics and provide a first layer of defense against natural outbreaks and potential engineered biological threats.
Intercept is joining a broader push among scientists and funders who have argued that respiratory infections have been accepted for too long as an unavoidable part of life. The new nonprofit is betting that with enough capital and sustained attention, that assumption can change.